Objective: This study was undertaken to quantify the relationship between prosthesis size adjusted for patient size (prosthesis-patient size) and long-term survival after aortic valve replacement.
The study has two unique features. First, it uses an analytic method that permits independent assessment of the association of prosthesis-patient size with long-, intermediate-, and short-term survivals. Second, it uses a large multiinstitutional group of patients to achieve sufficient statistical power to make these assessments. Purposes of the investigation were to quantify the relationship of prosthesis-patient size to long-, intermediate-, and short-term survivals and from this relationship to develop a clinically useful algorithm for identifying a prosthesis size below which survival might be affected.
Patients and Methods

Patients
Individual patient data on 13,258 AVRs were assembled from nine sources ( Table 1) . Included were adults at least 18 years old for whom prosthesis type, model, and labeled size were recorded. Excluded were patients with a preexisting valve prosthesis in a location other than aortic, those undergoing a multiple valve operation, those with native or prosthetic valve endocarditis, those undergoing emergency AVR, and those undergoing concomitant procedures other than coronary artery bypass grafting. Patients undergoing aortic root enlargement were not excluded. Half the operations were performed before 1990 (Table 1) .
Data with identifiers removed were assembled from existing registries and clinical research databases. Variables available across all sources are listed in Appendix 1. This combination of individual patient data from multiple sources has been termed a meta-analysis of individual patient data. 4 
Prostheses
Prostheses were of four varieties: stented porcine xenografts (n ϭ 5757, designated porcine), stented bovine pericardial xenografts (n ϭ 3198, designated pericardial), mechanical devices (n ϭ 3583, of which 2125 were bileaflet and 1458 were monoleaflet), and allografts (n ϭ 720). Patient characteristics varied according to variety of prosthesis received (Tables 2A and 2B ).
Prosthesis-Patient Size
Prosthesis size was normalized to patient size by relating geometric dimensions of the prosthesis to body surface area (BSA). We call this prosthesis-patient size. We have avoided the term prosthesis-patient mismatch because we made no a priori assumptions about what this might mean; rather, we examined the entire range of prosthesis-patient size in relation to survival.
Prosthesis size was defined in terms of geometric dimensions of prostheses, not in vitro or in vivo functional dimensions. These properties included the manufacturer's labeled size (in millimeters), which refers inconsistently to diameter of external sewing ring (mechanical prostheses), mounting ring (stented xenografts), or internal orifice (allografts), and the geometric internal orifice diameter (in millimeters), a consistent physical dimension (Appendix Table 1 ). 5 They did not include patient's tissue annulus diameter, a proposed ISO standard (ISO/CD 5840 working decrement) that was not recorded in any source. Patient size was represented by BSA, calculated from height and weight. 6 Prosthesis-patient size was expressed in two ways: as indexed orifice area (in square centimeters per square meter), calculated from prosthesis internal orifice diameter assuming a circular orifice shape and patient's BSA, and as standardized orifice size (Z), the number of SDs by which internal orifice diameter deviated from mean normal native aortic "annulus" (left ventriculoaortic junction) diameter for the patient's BSA (see Table 2B ). 7 Distributions of these expressions of prosthesis-patient size, stratified by prosthesis variety, are shown in Figure 1 . A). Instantaneous risk of death peaked immediately after operation, fell rapidly during the first 6 postoperative months, and then rose steadily (Figure 2 , B). These represent three additive hazard phases labeled early, constant, and late. To determine the independent influence of prosthesis-patient size on long-, intermediate-, and short-term survivals, a multiphase hazard decomposition method was used (available for use with the SAS system at http://www. clevelandclinic.org/heartcenter/hazard). Each hazard phase ( Figure  2 , B) incorporated an independent set of risk factors, permitting quantification of the effect of prosthesis-patient size within each time frame determined by the data themselves, not arbitrarily, without assuming proportional hazards.
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Risk adjustment. All variables listed in Appendix 1 were included in each hazard phase of all multivariable models, a saturated model risk-adjustment strategy (Appendix 2). 10 However, even saturated multivariable models may not account completely for confounding between selection of prosthesis size for a patient and outcome. Therefore a balancing score for each expression of prosthesis-patient size was constructed and included as a further adjustment in each hazard phase (Appendix 2).
11,12
Prosthesis-patient size and survival. Separate analyses were performed of the relation of risk-adjusted mortality to continuous values of indexed orifice area and standardized orifice size (Z). The specific linearizing transformations of scale for these (and other continuous variables) for each hazard phase were selected by bootstrap bagging (Appendix 2). 13, 14 Whenever computatively possible, effects of both large and small prosthesis-patient size were estimated (Appendix 3).
Clinical algorithm
An internal prosthesis orifice diameter was calculated across the spectrum of BSA below which increased risk of mortality might be anticipated. For this, formulas for indexed orifice area and standardized orifice size were rearranged and solved at fixed values of prosthesis-patient size.
Presentation
Survival curves are presented with both parametric and KaplanMeier estimates. Confidence limits are asymmetric and equivalent to 1 SE (68%). To illuminate multivariable findings, nomograms were constructed by solving the multivariable equations for a 70-year-old woman of 1.9 m 2 BSA with aortic stenosis, in New York Heart Association functional class III, and undergoing primary isolated AVR in the current era.
Results
Prosthesis Size and Non-Risk-Adjusted Survival
Small, nonsystematic survival differences were observed with respect to both indexed orifice area ( Figure 3 ) and standardized orifice size (Figure 4 ). Systematic survival decrements were found with decreasing labeled size (Ap- For differences among groups (parametric and nonparametric tests), all P Ͻ .0001. *Z score represents the number of SDs by which the internal prosthesis orifice size differs from the predicted mean normal native aortic valve size for that patient's body surface area.
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pendix Figure 1 , A) and according to variety of prosthesis (Appendix Figure 1, B) . However, these differences were largely accounted for by differing patient characteristics according to prosthesis size and variety (Table 2B and Appendix 2). ACD spectrum of prosthesis-patient size at 5, 10, and 15 years ( Figure 5 ). Short-term mortality. Mortality in the early hazard phase increased at the extreme of small prosthesis-patient size (Table 3) . Compared with the most favorable risk, 30-day mortality is predicted to increase 1% to 2% if indexed orifice area falls below 1.2 cm 2 /m 2 ( Figure 6 , A) or standardized orifice size falls below Ϫ2.5 Z (Figure 6 , B).
Prosthesis-Patient Size and Risk-Adjusted Survival
Clinical Algorithm
Prosthesis-patient size of 1.2 cm 2 /m 2 or Ϫ2.5 Z may be considered thresholds for prosthesis-patient size mismatch with respect to early survival. Prosthesis-patient size rarely fell below these critical values in patients receiving bioprostheses ( Figure 1) ; such sizes were more common among patients receiving mechanical prostheses.
By substituting either 1.2 cm 2 /m 2 or Ϫ2.5 Z into their respective formulas, a simple nomogram reveals the internal orifice size of a prosthesis at these thresholds for any BSA (Figure 7) . The nomogram can be used in the operating room by drawing a vertical line from a patient's BSA to the solid line and a horizontal line from there to the internal orifice diameter. Appendix Table A1 is then used to find the next largest labeled-size prosthesis that provides either indexed orifice area or standardized orifice size above these threshold values.
Discussion
Prosthesis-patient size mismatch leading to clinical symptoms and requiring reoperation is a reality, although much of the literature focuses on hemodynamics rather than clinical symptoms.
1,2 It is also recognized that prosthetic aortic valves present more impedance to left ventricular outflow than do normal native valves. Thus, manufacturers have concentrated on increasing prosthesis hemodynamic efficiency (performance). It is therefore surprising that the principal finding of this study was a failure to detect small prosthesis-patient size as a risk factor for intermediate-or long-term survival, consistent with smaller single-institution studies and moderately large multi-institution studies. [15] [16] [17] [18] [19] How can these results be explained when logic 
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suggests that sustained elevated transprosthesis energy loss should translate into decreased long-term survival? 20 First, the natural history of mild, fixed native aortic valve stenosis is unknown. Progressive aortic disease tends to become apparent in elderly persons; mild nonprogressive stenosis may be well tolerated. Second, patients who undergo AVR have lower long-term survival than an age-, sex-, and race-matched general population (Appendix Figure 2) . 6 Mortality is affected by complications of warfarin anticoagulation (particularly its variability 21 ) among patients with mechanical devices and by reoperation for structural valve degeneration among those with biologic prostheses. Yet in this study and others, 22 it has been difficult to demonstrate a survival difference according to prosthesis variety (Appendix 3). Thus, the multifactorial nature of reduced survival after AVR may mask subtle individual components of it, such as small prosthesis-patient size. Third, few prostheses, and almost no bioprostheses, had a prosthesis-patient size smaller than the 95% confidence limits of normal native human aortic valves (Ϫ2 Z). Thus, AVR as practiced in centers represented in this study is such that prosthesis-patient size is rarely excessively small. 23 Fourth, degenerative aortic valve stenosis is a disease of elderly patients with already limited lifespans. Although we searched for interactions of age with prosthesis-patient size and found none, elderly patients simply may not live long enough to manifest a survival decrement from small prosthesis-patient size. Fifth, the 1% to 2% increase in shortterm mortality found among patients with small prosthesispatient size may serve as a biologic selection process. However, our cohort of patients with such prostheses (1109 patients with a labeled size of 19 mm or smaller) was sufficiently large, short-term mortality sufficiently low, and survival sufficiently long to suggest that this is not an important explanation.
What seems to be secure information is that patients with particularly small prosthesis-patient size are exposed to a slight increase in short-term mortality, consistent with several reports. 16, [24] [25] [26] [27] [28] Pibarot and colleagues 25 attribute increased early risk to poorer postoperative cardiac performance. However, most reports of increased early risk associated with small prostheses have not been well risk adjusted because of being underpowered. For example, small prostheses are preferentially used in elderly patients (Appendix Table 3 ), and this may confound interpretation of outcome (Appendix Figure 2) . In this study, sufficient statistical power was available and an appropriate methodology was used to reliably examine short-term mortality.
This study does not resolve the dilemma of managing the small aortic root, at least with respect to short-term mortality. Some surgeons avoid inserting small prostheses, accepting the complexity and possible added risk of aortic root enlargement 29, 30 ; others, particularly when faced with an elderly patient with a small aortic root, insert a small prosthesis without an enlarging procedure. 31 Subannular or supra-annular positioning of the prosthesis may permit size upgrading. Stentless prostheses are highly advocated; however, their internal orifice may be smaller than that of a similarly labeled-size stented pericardial prosthesis. 32 These differing approaches to managing the small aortic root reflect differences of opinion regarding the adverse clinical impact of small prosthesis size.
Issues
At the time of its original presentation, in subsequent discussions of its findings, and among ourselves, this study raised several methodologic issues.
Statistical power and risk adjustment. Confounding reliable assessment of the relation of prosthesis size to mortality are differences in characteristics of patients receiving each size and variety of prosthesis, necessitating risk adjustment; inconsistencies between manufacturer's labeled size for various types of prosthesis, necessitating adoption of consistent expressions of prosthesis size; limitations of All variables in Appendix Table 2 were included in these models, as were balancing scores in each hazard phase. Thus, the estimates are adjusted for all these factors. Dashes refer to lack of an effect with a coefficient that is assumed to be zero. In most cases, it was not computatively possible to include a transformation of scale that would quantify an effect. *Inverse squared transformation, (1/indexed orifice area) 2 ; although a negative coefficient sign is expected for "smaller" and a positive sign for "larger," indicating direction of effect, linearizing transforms such as this reverse the signs. †Exponential transformation, exp (Z).
single-institution studies, particularly regarding number of patients receiving small prostheses, necessitating a multiinstitutional study; and low operative mortality, necessitating a large study with a sufficient number of deaths to achieve adequate statistical power. By amassing a large AVR database with a sufficient number of events (3898 deaths), we were available to achieve statistical power to identify even a small survival impact of prosthesis-patient size and to localize it to a specific follow-up time frame while adjusting simultaneously for many important patient variables, device models, data sources, and selection factors. Prosthesis size. Prosthesis size may be based on physical dimensions or functional performance. Physical dimensions include labeled size and internal orifice size. Because manufacturers' conventions for labeling prosthesis size differ among devices, we selected a common metric: geometric internal orifice diameter. 5 Functional size includes in vitro and in vivo effective orifice areas (EOAs). The former may be static at a variety of steady flow rates or dynamic with a variety of pulsatile waveforms and flow rates 33 ; the latter is estimated clinically under a range of incompletely controlled conditions in patients by echocardiography according to various formulas.
We have not included information about in vitro EOA, because methodology has been difficult to standardize and results are difficult to reproduce. We had no individual patient data on functional in vivo EOA. In vivo EOA varies from moment to moment with patient activity, 34, 35 cardiac output and blood pressure, and dynamics of the left ventricular outflow tract, as well as intrinsic prosthesis properties, although it is well correlated with geometric internal orifice area. 34 It is therefore possible that one or more individual patients had functional prosthesis-patient size mismatch that we did not evaluate. However, in vivo EOA is unavailable at the time of selecting a prosthesis at AVR. 
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Pibarot and colleagues 36 and Dumesnil and coworkers 34 have suggested that rather than using geometric prosthesis dimensions as a fixed reference for prosthesis size, a fixed referent value of in vivo EOA should be used, which they termed projected EOA. Referent values were obtained from informal meta-analysis of literature sources. To the extent that in vivo EOA differs importantly from a linear relation to geometric orifice area, substituting projected EOA for geometric size is advantageous. However, this strategy has several drawbacks: It suffers from flow dependency, large scatter in the data, rest versus exercise differences, and limited availability of data for each prosthesis size and model. Also, when fixed referent values are used for intraoperative decision making, they acquire the same limitations as the simpler geometric values used in this study. For intraoperative decision making, we therefore recommend using the relation of survival to prosthesis geometric orifice dimensions. Patient size. Native aortic valve size is related to somatic growth, as is cardiac output. The most consistent allometric relationship, then, is BSA. Normalization. Normalization of any expression of prosthesis size can be made to body size. Use of indexed valve area assumes a linear relation between valve area and BSA, which is nearly, but not completely, accurate. 6 Use of dimensionless standardized values (Z) is based on the variability of native annulus size among similarly sized healthy individuals. Rimoldi and Lev 37 introduced the idea that normality and abnormality can be expressed in terms of number of SDs away from normal size given a patient's cardiac structures measure. Thus, only 2.5% of the normal population have a valve size 2 SDs or more below mean normal size (Ϫ2 Z). Both mean normal value and its SD are estimated by regression analysis of normal patient data. 7 Then, given BSA and valve size, the regression equation is solved to yield estimated mean normal valve size and its SD, from which Z is calculated. 15 There is a logarithmic relation between indexed and standardized prosthesis-patient size. Standardized size expands the scale of small values compared with indexed values (contrast parts A and B of Figure 5 ).
Limitations
Despite the large AVR database used in this analysis, small prosthesis-patient size was rare. Only 28 patients had an indexed orifice area smaller than 0.85 cm 2 /m 2 . Nevertheless, we believe the information about prosthesis-patient size and survival is reliable down to an indexed orifice area of approximately 1.1 cm 2 /m 2 or 3 SDs below native aortic valve size.
An insurmountable limitation is that neither institution nor valve variety, model, or size was chosen randomly for a given patient. Nonrandom allocation introduces bias. Use of both saturated model techniques and balancing scores provides adjustment for known factors but no explicit protection against factors unavailable across all data sources or unrecorded factors (Appendix 2).
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A study like this relies on existing databases that contain a common set of identically defined and relevant variables, similar outcome assessment, and complete reporting. Not all known or purported risk factors for mortality after AVR were available in all data sets. Among the missing variables were ones related to ventricular morphology, measured ventricular function, and noncardiac comorbidities. These variables may not have been distributed uniformly across institutions and may interact with choice of valve prosthesis and size.
All-cause mortality was the end point. It is noninterpretative and was chosen despite the claim that valve-specific mortality is more sensitive. 16 In fact, reported causes of death are untrustworthy, particularly for elderly patients. 8 Nevertheless, it is a limitation that we do not know who died suddenly. Although reliable follow-up for survival estimates extended to 15 years, the mean was only 5.3 years. Long-term information requires inclusion of patients operated on in earlier eras, when operative mortality was higher than it is today; we attempted to adjust for this by including date of operation in all analyses.
A strength of this study is representativeness. Databases were solicited from investigators well known for heart valve investigation in North America and Europe and from two organizations responsible for multi-institutional heart valve registries. We also included the spectrum of valve varieties; however, a limitation is the absence of stentless xenografts. Except from one manufacturer, internal orifice size of stentless valves was claimed not to be available, although Rao and colleagues 32 have reported that the internal orifice size of a Toronto stentless prosthesis of labeled size 25 is equivalent to that of a pericardial stented prosthesis of labeled size 21. Allografts were therefore considered to represent stentless devices, despite their use primarily in young and middle-aged patients (only 10% of recipients were older than 67 years). 38 
Inferences
Surgical. Within the constraints of prudent AVR in these institutions, we identified no relationship between prosthetic-patient size and intermediate-and long-term survivals. However, we found a small increase in early mortality among patients who received prostheses with small valve orifices in relationship to body size. Although we recognize that outcome after AVR is related to many factors, 39 with currently available prostheses few patients should require aortic root enlargement with its attendant complexity, prolonged operative time, and risks of bleeding, heart block, and mortality, 29 particularly if a bioprosthesis is used.
Manufacturing. This study challenges the value of concentrating on better hemodynamic performance. Rather, to improve long-term survival, a durable nonthrombogenic prosthesis is needed that would permit operation much earlier in the natural history of aortic valve disease, before secondary left ventricular remodeling takes place and the patient reports important symptoms.
We thank Tess Knerik for editorial assistance and data managers at each source of information. least P ϭ .05. In the early hazard phase, there was a 90% probability that smaller indexed orifice area was associated with higher mortality, including an 8% probability that both smaller and larger size were associated. For standardized orifice size, the corresponding probabilities were 90% and 60%.
In contrast, in the constant hazard phase there was a 20% probability that smaller indexed orifice area was associated with higher mortality, including a 6% probability that both smaller and larger size were associated. For standardized orifice size, the corresponding probabilities were 46% and 4.5%.
In the late hazard phase there was a 25% probability that smaller indexed orifice area was associated with mortality, including a 2% probability that both smaller and larger size were associated. For standardized orifice size, the corresponding probabilities were 24% and 25%.
Search for modulating factors. Interactions between patient factors and expressions of prosthesis-patient size that might modulate these estimates of magnitude of risk were not statistically significant (P Ͼ .1). In particular, the pattern of risk in elderly men with aortic stenosis receiving small prostheses was no different from that determined for the entire study group (P ϭ .9). 42 Interactions between prosthesis-patient size and valve models did not modulate survival.
Discussion
Dr David H. Adams (Boston, Mass) . Dr Blackstone, I, like most people in the audience, continue to learn from you. By combining a pool of nine multi-institutional databases, you are in a good position to answer some of the important clinical questions associated with aortic valve prosthesis size and operative mortality. Your conclusion that small aortic prostheses increased operative mortality by 1% in 10% of patients is statistically elegant. In the manuscript version that I read, you concluded rather strongly that "this study settles the debate about whether smaller aortic prosthesis size in the range used clinically adversely influences
